Product approvals

In this June 13, 2019, photo released by Xinhua News Agency, guests, from left, Yi Huiman, chairman of China Securities Regulatory Commission, Liu He, vice premier, Li Qiang, top party official of Shanghai, and Ying Yong, Shanghai's mayor, celebrate the launch of the SSE STAR Market, previously referred to as the Shanghai science and technology innovation board in Shanghai. Trading is expected to start Monday, July 22, 2019 on the Chinese stock market for high-tech companies that play a key role in official development plans that are straining relations with Washington. (Fang Zhe/Xinhua via AP)
July 18, 2019 - 1:25 am
BEIJING (AP) — Trading starts Monday on a Chinese stock market for high-tech companies that play a key role in official development plans that are straining relations with Washington. Regulators have approved 25 companies in information technology and other fields seen by communist leaders as a...
Read More
This image provided by Amag Pharmaceuticals in June 2019 shows packaging for their drug Vyleesi. The medication OK'd Friday, June 21, 2019 by the U.S. Food and Drug Administration is only the second approved to increase sexual desire in a women, a market drugmakers have been trying to cultivate since the blockbuster success of Viagra for men in the late 1990s. (Amag Pharmaceuticals via AP)
June 21, 2019 - 6:20 pm
WASHINGTON (AP) — U.S. women will soon have another drug option designed to boost low sex drive: a shot they can give themselves in the thigh or abdomen that raises sexual interest for several hours. The medication OK'd Friday by the Food and Drug Administration is only the second approved to...
Read More
This photo provided by Novartis shows Zolgensma. The one-time gene therapy developed by Novartis, Zolgensma, will cost $2.125 million. It treats a rare condition called spinal muscular atrophy, or SMA, which strikes about 400 babies born in the U.S. each year. The therapy, given in a one-hour infusion, was approved for children under age 2 and will be available within two weeks. (Novartis via AP)
May 24, 2019 - 5:51 pm
U.S. regulators have approved the most expensive medicine ever, for a rare disorder that destroys a baby's muscle control and kills nearly all of those with the most common type of the disease within a couple of years. The treatment is priced at $2.125 million. Out-of-pocket costs for patients will...
Read More
FILE- In this March 11, 2019, file photo rescuers work at the scene of an Ethiopian Airlines flight crash near Bishoftu, or Debre Zeit, south of Addis Ababa, Ethiopia. Investigators have determined that an anti-stall system automatically activated before the Ethiopian Airlines Boeing 737 Max jet plunged into the ground, The Wall Street Journal reported Friday, March 29. (AP Photo/Mulugeta Ayene, File)
March 30, 2019 - 12:24 am
Boeing is facing mounting pressure to roll out a software update on its best-selling plane in time for airlines to use the jets during the peak summer travel season. Company engineers and test pilots are working to fix anti-stall technology on the Boeing 737 Max that is suspected to have played a...
Read More
FILE - This Oct. 14, 2015 file photo shows the Food & Drug Administration campus in Silver Spring, Md. On Friday, March 8, 2019, the FDA approved Roche’s Tecentriq, the first cancer immunotherapy for treating an aggressive type of breast cancer. (AP Photo/Andrew Harnik, File)
March 08, 2019 - 6:26 pm
The U.S. Food and Drug Administration has approved the first immunotherapy drug for breast cancer. Swiss drugmaker Roche's Tecentriq was OK'd Friday for treating advanced triple-negative breast cancer, which accounts for about 15 percent of cases. It's to be given with chemotherapy, the standard...
Read More
This photo provided by Janssen Global Services shows Spravato nasal spray. Spravato, a mind-altering medication related to the club drug Special K, won U.S. approval Tuesday, March 5, 2019, for patients with hard-to-treat depression, the first in a series of long-overlooked substances being reconsidered for severe forms of mental illness. (Janssen Global Services via AP)
March 06, 2019 - 3:07 am
WASHINGTON (AP) — A mind-altering medication related to the club drug Special K won U.S. approval Tuesday for patients with hard-to-treat depression, the first in a series of long-overlooked substances being reconsidered for severe forms of mental illness. The nasal spray from Johnson & Johnson...
Read More
FILE - In this Oct. 17, 2018, file photo a depiction of a cannabis bud drops from the ceiling at Leafly's countdown party in Toronto as midnight passes and marks the first day of the legalization of cannabis across Canada. The last year was a 12-month champagne toast for the legal marijuana industry as the global market exploded and cannabis pushed its way further into the financial and cultural mainstream. Canada ushered in broad legalization, U.S. drug regulators approved the first cannabis-based drug and investors pumped in billions of dollars. (Chris Young/The Canadian Press via AP, File)
December 27, 2018 - 3:44 pm
PORTLAND, Ore. (AP) — The last year was a 12-month champagne toast for the legal marijuana industry as the global market exploded and cannabis pushed its way further into the financial and cultural mainstream. Liberal California became the largest legal U.S. marketplace, conservative Utah and...
Read More
FILE - In this Jan. 18, 2017 photo marijuana is displayed for sale at a shop in Juneau, Alaska. Alaska regulators approved rules for onsite consumption of marijuana at specially designated shops on Thursday, Dec. 20, 2018, a significant step for the cannabis industry after years of debate. (AP Photo/Mark Thiessen, File)
December 20, 2018 - 7:27 pm
JUNEAU, Alaska (AP) — Alaska regulators on Thursday approved rules for onsite consumption of marijuana at specially designated shops, a significant step for the cannabis industry in the state after years of debate. The 3-2 vote by the Marijuana Control Board does not mean people can light up at...
Read More
November 26, 2018 - 12:04 pm
WASHINGTON (AP) — US health officials said Monday they plan to overhaul the nation's decades-old system for approving most medical devices, which has long been criticized by experts for failing to catch problems with risky implants and medical instruments. The Food and Drug Administration announced...
Read More
This undated image provided by AcelRx Pharmaceuticals shows the dispenser and a tablet for the company's medication Dsuvia. On Friday, Nov. 2. 2018, U.S. regulators announced the approval of the fast-acting, super-potent opioid tablet as an alternative to IV painkillers used in hospitals. (Craig Sherod Photography/AcelRx Pharmaceuticals via AP)
November 02, 2018 - 3:24 pm
TRENTON, N.J. (AP) — U.S. regulators on Friday approved a fast-acting, super-potent opioid tablet as an alternative to IV painkillers used in hospitals. The decision by the Food and Drug Administration on Friday came over objections from critics who fear the pill will be abused. In a lengthy...
Read More

Pages